Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-alpha, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung-Wook | - |
dc.contributor.author | Kim, Hyo Jong | - |
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Dong, Suk Ho | - |
dc.contributor.author | Kim, Byung-Ho | - |
dc.contributor.author | Chang, Young Woon | - |
dc.contributor.author | Chi, Sung-Gil | - |
dc.date.accessioned | 2021-09-05T02:32:13Z | - |
dc.date.available | 2021-09-05T02:32:13Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 0163-2116 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96642 | - |
dc.description.abstract | Background Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-kappa B in response to tumor necrosis factor (TNF)-alpha. Aims To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-alpha signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy. Methods In total, 31 IFX therapy-naive patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-alpha and PRKCDBP expression was performed in rectal biopsies. Results A significant correlation was observed in immunoreactivity between TNF-alpha and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-alpha (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-alpha decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-alpha levels pre- and post-therapy (Spearman's rank correlation test; P = 0.005 and P = 0.001, respectively). Conclusions These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-alpha expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-alpha. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-alpha, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-alpha PRKCDBP signaling pathway. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject | CROHNS-DISEASE | - |
dc.subject | FECAL CALPROTECTIN | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | THERAPY | - |
dc.subject | MUCOSA | - |
dc.subject | INACTIVATION | - |
dc.subject | LACTOFERRIN | - |
dc.subject | PREDICTORS | - |
dc.subject | CANCERS | - |
dc.title | Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-alpha, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chi, Sung-Gil | - |
dc.identifier.doi | 10.1007/s10620-014-3282-4 | - |
dc.identifier.scopusid | 2-s2.0-84912523063 | - |
dc.identifier.wosid | 000345322100013 | - |
dc.identifier.bibliographicCitation | DIGESTIVE DISEASES AND SCIENCES, v.59, no.12, pp.2947 - 2957 | - |
dc.relation.isPartOf | DIGESTIVE DISEASES AND SCIENCES | - |
dc.citation.title | DIGESTIVE DISEASES AND SCIENCES | - |
dc.citation.volume | 59 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2947 | - |
dc.citation.endPage | 2957 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | FECAL CALPROTECTIN | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MUCOSA | - |
dc.subject.keywordPlus | INACTIVATION | - |
dc.subject.keywordPlus | LACTOFERRIN | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | CANCERS | - |
dc.subject.keywordAuthor | Immunohistochemistry | - |
dc.subject.keywordAuthor | Infliximab | - |
dc.subject.keywordAuthor | PRKCDBP | - |
dc.subject.keywordAuthor | Tumor necrosis factor-alpha | - |
dc.subject.keywordAuthor | Ulcerative colitis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.